Katsuta Eriko, Yan Li, Opyrchal Mateusz, Kalinski Pawel, Takabe Kazuaki
Breast Surgery, Department of Surgical Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Ther Adv Med Oncol. 2021 Apr 5;13:17588359211006680. doi: 10.1177/17588359211006680. eCollection 2021.
Cytotoxic T-lymphocyte (CTL) infiltration into tumor is a positive prognostic factor in breast cancer. High tumor mutational burden (TMB) is also considered as a predictor of tumor immunogenicity and response to immunotherapy. However, it is unclear whether the infiltration of functional CTL simply reflects the TMB or represents an independent prognostic value.
Utilizing The Cancer Genome Atlas (TCGA) breast cancer cohort, we established the Functional Hotness Score (FHS). The associations of FHS and breast cancer patient prognosis as well as distinct immunity markers were analyzed in a total of 3011 breast cancer patients using TCGA, METABRIC and metastatic breast cancer (MBC) cohort GSE110590.
We established FHS, based on , and gene expression levels of bulk tumors, which delivered the best prognostic value among some gene combinations. Breast cancer patients with the high-FHS tumors showed significantly better survival. FHS was lower in the MBCs. Triple-negative breast cancer (TNBC) showed the highest FHS among subtypes. FHS predicted patient survival in hormone receptor (HR)-negative, especially in TNBC, but not in HR-positive breast cancer. FHS predicted patient prognosis independently in TNBC. The high-FHS TNBCs showed not only higher CD8+ T cell infiltration, but also enhanced broader type-1 anti-cancer immunity. The patients with the high-FHS tumors showed better prognosis not only in high-TMB tumors but also in low-TMB TNBCs. The combination of high-TMB with high-FHS identified a unique subset of patients who do not recur over time in TNBC.
TNBCs with high FHS based on the expression levels of , and showed improved prognosis with enhanced anti-cancer immunity regardless of TMB. FHS constitutes an independent prognostic marker of survival, particularly robustly when combined with TMB in TNBC.
细胞毒性T淋巴细胞(CTL)浸润肿瘤是乳腺癌的一个阳性预后因素。高肿瘤突变负荷(TMB)也被视为肿瘤免疫原性和免疫治疗反应的一个预测指标。然而,尚不清楚功能性CTL的浸润是仅仅反映了TMB,还是代表着一种独立的预后价值。
利用癌症基因组图谱(TCGA)乳腺癌队列,我们建立了功能热点评分(FHS)。使用TCGA、METABRIC和转移性乳腺癌(MBC)队列GSE110590,在总共3011例乳腺癌患者中分析了FHS与乳腺癌患者预后以及不同免疫标志物之间的关联。
我们基于实体瘤的 、 和 基因表达水平建立了FHS,在一些基因组合中,它具有最佳的预后价值。FHS高的肿瘤的乳腺癌患者显示出明显更好的生存率。MBC中的FHS较低。三阴性乳腺癌(TNBC)在各亚型中FHS最高。FHS可预测激素受体(HR)阴性患者的生存情况,尤其是TNBC患者,但不能预测HR阳性乳腺癌患者的生存情况。在TNBC中,FHS可独立预测患者预后。FHS高的TNBC不仅显示出更高的CD8 + T细胞浸润,还增强了更广泛的1型抗癌免疫。FHS高的肿瘤患者不仅在高TMB肿瘤中,而且在低TMB的TNBC中都显示出更好的预后。高TMB与高FHS的组合确定了TNBC中一组随时间不复发的独特患者亚群。
基于 、 和 表达水平的FHS高的TNBC显示出抗癌免疫力增强,预后改善,且与TMB无关。FHS构成生存的独立预后标志物,在TNBC中与TMB联合时尤其有力。